Abstract Library

#2910 Virotherapy Shows Promising Efficacy in Neuroendocrine Cancers

Introduction: So far, there have been only two clinical studies using virotherapeutics to treat neuroendocrine cancers (NCT00314925 & NCT02749331). Notably, none of these approaches employed a clinically approved virotherapeutic compound.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Lauer U

Authors: Lauer U, Berchtold S, Smirnow I, Schaller M, Fehrenbacher B,

Keywords: neuroendocrine, cancer, virotherapy, virotherapeutics, preclinical, research,

#1205 Temozolomid-Based Therapy in GEP-and Bronchopulmonary NEN from a Multicentric Study from Germany

Introduction: Chemotherapy (CTx) with temozolomid as mono (TEM) or combination therapy with capcitabine (TEM/CAP) is a new cytotoxic regimen with good efficiency in pancreatic and bronchopulmonary NET-G1/G2 and NEC-G3.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Maasberg S, Bacher M, Rinke A, Lahner H, Unger N,

Keywords: temozolomide, capecitabine,

#1201 Results of Sunitinib Treatment of Advanced Neuroendocrine Neoplasms: “Real-life” Outcome Data from the German NET-Register

Introduction: Among modern treatments (Tx) for neuroendocrine neoplasms (NEN) sunitinib (SUN) has impacted Tx of primarily pancreatic NEN (pNEN).

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Bacher M, Maasberg S, Fottner C, Begum N, Quietzsch D,

Keywords: sunitinib, outcome,

#1200 Clinical Outcome of Everolimus Treatment of Advanced Neuroendocrine Neoplasms: “Real-life” Data from the German NET-Register

Introduction: Everolimus (EVE) has importantly impacted the treatment (Tx) of mostly pancreatic NEN.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Pape U

Authors: Pape U, Bacher M, Fottner C, Lahner H, Begum N,

Keywords: everolimus, outcome,